Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for Menopausal Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women age 40 years old or older~* Menopausal symptoms of at least 3 months duration, including irregular periods and/or hot flushes~* Minimum score of 15 on the Hamilton Rating Scale for Depression (17-item),~* Patients will meet criteria for a major depressive episode, verified using the Mini International Neuropsychiatric Interview (MINI).~* Subjects will be able to be treated on an outpatient basis, and~* Subjects will be able to provide written informed consent~Exclusion Criteria:~* Subjects presently taking antidepressant medication,~* Subjects currently using hormone replacement therapy,~* Other Axis I disorders, except Generalized Anxiety Disorder or Panic Disorder, according to the Mini International Neuropsychiatric Interview (MINI)~* uncontrolled narrow angle glaucoma~* known hypersensitivity to duloxetine or any of the inactive ingredients~* treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization or potential need to use an MAOI during the study or within 5 days of discontinuation of study drug.~* Presence of psychotic symptoms,~* History of mania or hypomania,~* HAM-D suicide item score \> 3,~* End stage renal disease or severe renal impairment~* Abnormal uterine bleeding (heavy or prolonged uterine bleeding, menstrual periods occurring more frequently than every 3 weeks, bleeding after sexual intercourse, spotting between periods) that has not been evaluated by a gynecologist.~* Subjects with serious or unstable medical illness, including alcohol or substance abuse, cardiovascular, hepatic, respiratory, endocrine, neuralgic, or hematologic disease, history of seizure disorder~* Subjects taking medications that may interact with duloxetine

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): After a one-week placebo lead-in, all eligible subjects will receive Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg Duloxetine per day for 7 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).